

DAFTAR PUSTAKA

1. Kementerian Kesehatan RI. PROFIL KESEHATAN INDONESIA 2021. 2022.
2. WHO Coronavirus (COVID-19) Dashboard [Internet]. WHO. [cited 2023 Nov 19]. Available from: <https://covid19.who.int/table>
2. Pelayanan Kesehatan Di Masa Pandemi P, Halim Sukur M, Kurniadi B, Faradillahisari RN. Covid-19 Dalam Perspektif Hukum Kesehatan. Vol. 1, Journal Inicio Legis. 2020.
4. Rachmawati. Update Covid-19 di Aceh, Sumut, Sumbar, Riau, Kepri, Jambi dan Bengkulu 20 Mei 2023 [Internet]. Kompas.com. 2023 [cited 2024 Jun 15]. Available from: <https://regional.kompas.com/read/2023/05/20/193000778/update-covid-19-di-aceh-sumut-sumbar-riau-kepri-jambi-dan-bengkulu-20-mei>
5. Provinsi Sumatera Barat dalam Angka 2022. 2022.
6. Provinsi Sumatera Barat dalam Angka 2023. 2023.
7. Eybpoosh S, Haghdoost AA, Mostafavi E, Bahrapour A, Azadmanesh K, Zolala F. Molecular epidemiology of infectious diseases. Electron Physician. 2017;9(8):5149–58.
8. D'Cruz RJ, Currier AW, Sampson VB. Laboratory Testing Methods for Novel Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2). Vol. 8, Frontiers in Cell and Developmental Biology. Frontiers Media S.A.; 2020.
9. Centers for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and Definitions [Internet]. 2023 [cited 2024 Feb 19]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/variants/>
10. Jhun H, Park HY, Hisham Y, Song CS, Kim S. SARS-CoV-2 Delta (B.1.617.2) variant: A unique T478K mutation in receptor binding motif (RBM) of spike gene. Vol. 21, Immune Network. Korean Association of Immunologists; 2021.
11. Bari MS, Hossain MJ, Akhter S, Emran TB. Delta variant and black fungal invasion: A bidirectional assault might worsen the massive second/third stream of COVID-19 outbreak in South-Asia. Ethics Med Public Health. 2021 Dec 1;19.

12. Alsaedi A, Alharbi M, Ossenkopp J, Farahat F, Taguas R, Algarni M, et al. Epidemiological and molecular description of nosocomial outbreak of COVID-19 Alpha (B.1.1.7) variant in Saudi Arabia. *J Infect Public Health*. 2022 Nov 1;15(11):1279–86.
13. Dewey FE, Grove ME, Pan C, Goldstein BA, Bernstein JA, Chaib H, et al. Clinical interpretation and implications of whole-genome sequencing. *JAMA*. 2014 Mar 12;311(10):1035–44.
14. Lorenzo-Redondo R, Ozer EA, Achenbach CJ, D'Aquila RT, Hultquist JF. Molecular epidemiology in the HIV and SARS-CoV-2 pandemics. Vol. 16, *Current Opinion in HIV and AIDS*. Lippincott Williams and Wilkins; 2021. p. 11–24.
15. Hare D, Dembicka KM, Brennan C, Campbell C, Sutton-Fitzpatrick U, Stapleton PJ, et al. Whole-genome sequencing to investigate transmission of SARS-CoV-2 in the acute healthcare setting: a systematic review. Vol. 140, *Journal of Hospital Infection*. W.B. Saunders Ltd; 2023. p. 139–55.
16. Ren SY, Wang WB, Gao RD, Zhou AM. Omicron variant (B.1.1.529) of SARS-CoV-2: Mutation, infectivity, transmission, and vaccine resistance. *World J Clin Cases*. 2022 Jan 7;10(1):1–11.
17. Tim Komunikasi Komite Penanganan Corona Virus Disease 2019 (COVID-19) dan Pemulihan Ekonomi Nasional. Melakukan Solusi Paralel dan Kolektif Dapat Mengantisipasi Varian Mempengaruhi Efikasi Vaksin [Internet]. 2021 [cited 2024 Feb 19]. Available from: Tim Komunikasi Komite Penanganan Corona Virus Disease 2019 (COVID-19) dan Pemulihan Ekonomi Nasional
18. Hartono, Yusuf Y. Tinjauan Molekuler dan Epidemiologi Mutasi pada Virus SARS-CoV-2. *Jurnal Bionature*. 2021;22(1).
19. Berno G, Fabeni L, Matusali G, Gruber CEM, Rueca M, Giombini E, et al. SARS-CoV-2 Variants Identification: Overview of Molecular Existing Methods. Vol. 11, *Pathogens*. MDPI; 2022.
20. Burrell CJ, Howard CR, Murphy FA. Pathogenesis of Virus Infections. In: Fenner and White's Medical Virology. Elsevier; 2017. p. 77–104.
21. Sanjuán R, Domingo-Calap P. Mechanisms of viral mutation. Vol. 73, *Cellular and Molecular Life Sciences*. Birkhauser Verlag AG; 2016. p. 4433–48.
22. Rubio L, Galipienso L, Ferriol I. Detection of Plant Viruses and Disease Management: Relevance of Genetic Diversity and Evolution. Vol. 11, *Frontiers in Plant Science*. Frontiers Media S.A.; 2020.

23. Cann AJ. Genomes. In: Principles of Molecular Virology. Elsevier; 2012. p. 55–101.
24. Haitao T, Vermunt J V., Abeykoon J, Ghamrawi R, Gunaratne M, Jayachandran M, et al. COVID-19 and Sex Differences: Mechanisms and Biomarkers. Vol. 95, Mayo Clinic Proceedings. Elsevier Ltd; 2020. p. 2189–203.
25. Mahata LE, Lailani M, Rezvi S, Putra SP, Putra AE. Age and Sex Differences in COVID-19 Clinical Symptom: Analysis of 19,588 Indonesian Cases. Open Access Maced J Med Sci. 2022 Apr 16;10(E):643–6.
26. Costagliola G, Spada E, Consolini R. Age-related differences in the immune response could contribute to determine the spectrum of severity of COVID-19. Vol. 9, Immunity, Inflammation and Disease. John Wiley and Sons Inc; 2021. p. 331–9.
27. Speranza E, Purushotham JN, Port JR, Schwarz B, Flagg M, Williamson BN, et al. Age-related differences in immune dynamics during SARS-CoV-2 infection in rhesus macaques. Life Sci Alliance. 2022 Apr 1;5(4).
28. Bajaj V, Gadi N, Spihlman AP, Wu SC, Choi CH, Moulton VR. Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections? Vol. 11, Frontiers in Physiology. Frontiers Media S.A.; 2021.
29. SM Rezvi. Analisis Gen RdRp pada Varian Virus SARS CoV-2. 2022;
30. Cahyani I, Putro EW, Ridwanuloh AM, Wibowo S, Hariyatun H, Syahputra G, et al. Genome Profiling of SARS-CoV-2 in Indonesia, ASEAN and the Neighbouring East Asian Countries: Features, Challenges and Achievements. Viruses. 2022 Apr 1;14(4).
31. Loconsole D, Centrone F, Morcavallo C, Campanella S, Accogli M, Sallustio A, et al. Changing features of COVID-19: Characteristics of infections with the SARS-CoV-2 Delta (B.1.617.2) and alpha (B.1.1.7) variants in Southern Italy. Vaccines (Basel). 2021 Nov 1;9(11).
32. Haryono, Rubaya AK, Husein A. Pengantar Epidemiologi. DI Yogyakarta: Poltekkes Joga Press; 2021.
33. Riley LW. Molecular Epidemiology. Bacterial Infections of Humans: Epidemiology and Control. Springer US; 2009.
34. Friis RH, Sellers TA. Epidemiology for public health practice. Jones & Bartlett Learning; 2014. 804 p.
35. Friis RH. Epidemiology 101. Second Edition. 2018.

36. Alsharif W, Qurashi A. Effectiveness of COVID-19 diagnosis and management tools: A review. Vol. 27, Radiography. W.B. Saunders Ltd; 2021. p. 682–7.
37. Khan M, Adil SF, Alkhathlan HZ, Tahir MN, Saif S, Khan M, et al. COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far. *Molecules*. 2021;26(39).
38. Bulut C, Kato Y. Epidemiology of covid-19. Vol. 50, Turkish Journal of Medical Sciences. Turkiye Klinikleri; 2020. p. 563–70.
39. Alfarouk KO, Alhoufie STS, Ahmed SBM, Shabana M, Ahmed A, Alqahtani SS, et al. Pathogenesis and management of COVID-19. Vol. 11, *Journal of Xenobiotics*. MDPI; 2021. p. 77–93.
40. Bakhshandeh B, Jahanafrooz Z, Abbasi A, Goli MB, Sadeghi M, Mottaqi MS, et al. Mutations in SARS-CoV-2; Consequences in structure, function, and pathogenicity of the virus. Vol. 154, *Microbial Pathogenesis*. Academic Press; 2021.
41. Helmy YA, Fawzy M, Elswad A, Sobieh A, Kenney SP, Shehata AA. The COVID-19 pandemic: A comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. *J Clin Med*. 2020 Apr 1;9(4).
42. Pascarella G, Strumia A, Piliago C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. Vol. 288, *Journal of Internal Medicine*. Blackwell Publishing Ltd; 2020. p. 192–206.
43. Thakur S, Sasi S, Pillai SG, Nag A, Shukla D, Singhal R, et al. SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines. Vol. 9, *Frontiers in Medicine*. Frontiers Media S.A.; 2022.
44. Hendaus MA, Jomha FA. Delta variant of COVID-19: A simple explanation. Vol. 2021, *Qatar Medical Journal*. HBKU Press; 2021.
45. Aleem A, Akbar AB, Vaqar S. Emerging Variants of SARS-CoV-2 and Novel Therapeutics Against Coronavirus (COVID-19). In *StatPearls Publishing*; 2023 [cited 2024 May 14]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK570580/>
46. Tracking SARS-CoV-2 variants [Internet]. World Health Organization. 2021 [cited 2024 May 14]. Available from: <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>
47. Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness

- against SARS-CoV-2 and variants of concern: a narrative review. Vol. 28, *Clinical Microbiology and Infection*. Elsevier B.V.; 2022. p. 202–21.
48. Otto SP, Day T, Arino J, Colijn C, Dushoff J, Li M, et al. The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic. Vol. 31, *Current Biology*. Cell Press; 2021. p. R918–29.
49. Choi JY, Smith DM. SARS-CoV-2 variants of concern. Vol. 62, *Yonsei Medical Journal*. Yonsei University College of Medicine; 2021. p. 961–8.
50. SARS-CoV-2 Variant Classifications and Definitions [Internet]. Centers for Disease Control and Prevention. 2023 [cited 2024 May 14]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html>
51. Kategori Usia [Internet]. Kementerian Kesehatan Republik Indonesia. [cited 2024 Jul 16]. Available from: <https://ayosehat.kemkes.go.id/kategori-usia>
52. SeyedAlinaghi SA, Mirzapour P, Dadras O, Pashaei Z, Karimi A, MohsseniPour M, et al. Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review. Vol. 26, *European Journal of Medical Research*. BioMed Central Ltd; 2021.
53. Burhan E. Pedoman tatalaksana COVID-19. 2020. 138 p.
54. Luring A, B E. Genetic Variants of SARS-CoV-2—What Do They Mean? *Journal American Medical Association*. 2021;
55. Boraschi D, et al. Clinical characteristics and viral RNA load in hospitalized and non-hospitalized COVID-19 patients: a cohort study. *Journal Of Clinical Virology*. 2021;134.
56. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science* (1979). 2021 Apr 9;372(6538).
57. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data – from vision to reality. Vol. 22, *Eurosurveillance*. European Centre for Disease Prevention and Control (ECDC); 2017.
58. Gunadi, Wibawa H, Marcellus, Hakim MS, Daniwijaya EW, Rizki LP, et al. Full-length genome characterization and phylogenetic analysis of SARS-CoV-2 virus strains from Yogyakarta and Central Java, Indonesia. *PeerJ*. 2020 Dec 21;8.
59. Tokgun O, Caliskan A, Coskun C, Tokgun PE, Akca H. Whole Genome Sequencing and Phylogenetic Analysis of SARS CoV 2 strains in Turkey. *J Infect Dev Ctries*. 2021 Apr 1;15(4):470–7.

60. Equestre M, Marcantonio C, Marascio N, Centofanti F, Martina A, Simeoni M, et al. Characterization of SARS-CoV-2 Variants in Military and Civilian Personnel of an Air Force Airport during Three Pandemic Waves in Italy. *Microorganisms*. 2023 Nov 1;11(11).
61. Alsaedi A, Alharbi M, Ossenkopp J, Farahat F, Taguas R, Algarni M, et al. Epidemiological and molecular description of nosocomial outbreak of COVID-19 Alpha (B.1.1.7) variant in Saudi Arabia. *J Infect Public Health*. 2022 Nov 1;15(11):1279–86.
62. Wang S, Zou X, Li Z, Fu J, Fan H, Yu H, et al. Analysis of Clinical Characteristics and Virus Strains Variation of Patients Infected With SARS-CoV-2 in Jiangsu Province—A Retrospective Study. *Front Public Health*. 2021 Dec 24;9.
63. Kim JS, Jang JH, Kim JM, Chung YS, Yoo CK, Han MG. Genome-Wide Identification and Characterization of Point Mutations in the SARS-CoV-2 Genome. *Osong Public Health Res Perspect*. 2020 Jun 1;11(3):101–11.
64. Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat Microbiol*. 2020 Nov 1;5(11):1403–7.
65. Mistry P, Barmania F, Mellet J, Peta K, Strydom A, Viljoen IM, et al. SARS-CoV-2 Variants, Vaccines, and Host Immunity. Vol. 12, *Frontiers in Immunology*. Frontiers Media S.A.; 2022.
66. Cahyani I, Putro EW, Ridwanuloh AM, Wibowo S, Hariyatun H, Syahputra G, et al. Genome Profiling of SARS-CoV-2 in Indonesia, ASEAN and the Neighbouring East Asian Countries: Features, Challenges and Achievements. *Viruses*. 2022 Apr 1;14(4).
67. Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreira IATM, et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. *Nature*. 2021 Nov 4;599(7883):114–9.
68. RS Sardjito. Deteksi dan Identifikasi Varian Virus SARS-CoV-2 [Internet]. Patologi Klinik RSUP Dr. Sardjito Yogyakarta. 2022 [cited 2024 Nov 20]. Available from: <https://sardjito.co.id/2022/03/09/deteksi-dan-identifikasi-varian-virus-sars-cov-2/>
69. RS Sardjito. Virus SARS-CoV-2 Variant of Concern Omicron [Internet]. KSM Paru RSUP Dr. Sardjito Yogyakarta. 2022 [cited 2024 Nov 20]. Available from: <https://sardjito.co.id/2022/03/09/virus-sars-cov-2-variant-of-concern-Omicron/>
70. Hansen PR, Andersen T, Chernozhukov V, Dalgaard P, Dyckman E, Ekstrøm C, et al. Relative Contagiousness of Emerging Virus Variants: An

Analysis of the Alpha, Delta, and Omicron SARS-CoV-2 Variants *
 [Internet]. 2022. Available from:
<https://twitter.com/ProfPHansen/status/1353808634652708864>

71. Tadiri CP, Gisinger T, Willer AK, Kublickiene K, Herrero MT, Raparelli V, et al. The influence of sex and gender domains on COVID-19 cases and mortality. *Can Med Assoc J* [Internet]. 2021;192(36). Available from: <https://cihr-irsc.gc.ca/e/>
72. Lee BR, Harrison CJ, Myers AL, Jackson MA, Selvarangan R. Differences in pediatric SARS-CoV-2 symptomology and Co-infection rates among COVID-19 Pandemic waves. *Journal of Clinical Virology*. 2022 Sep 1;154.
73. Shoji K, Akiyama T, Tsuzuki S, Matsunaga N, Asai Y, Suzuki S, et al. Clinical characteristics of COVID-19 in hospitalized children during the Omicron variant predominant period. *Journal of Infection and Chemotherapy*. 2022 Nov 1;28(11):1531–5.
74. Satdhabudha A, Chaikulsil C, Sritipsukho P, Sinlapamongkolkul P, Chaumrattanakul U, Tangsathapornpong A, et al. Epidemiological and Clinical Characteristics of Pediatric COVID-19 in the Tertiary Care System in Thailand: Comparative Delta and pre-Delta Era. *Mediterr J Hematol Infect Dis*. 2022;14(1).
75. Alteri C, Scutari R, Costabile V, Colagrossi L, Yu La Rosa K, Agolini E, et al. Epidemiological characterization of SARS-CoV-2 variants in children over the four COVID-19 waves and correlation with clinical presentation. *Sci Rep*. 2022 Dec 1;12(1).
76. Sarvasti D. Pengaruh Gender Dan Manifestasi Kardiovaskular Pada COVID-19. *Indonesian Journal of Cardiology*. 2020 Jun 1;41(2):126–32.
77. Chairani I, Pusat B, Papua SP. Dampak Pandemi COVID-19 dalam Perspektif Gender di Indonesia. 2020;39–42. Available from: <http://www.nber.org/papers/w26947>
78. Sumakul MK, Rampengan NH, Rompies R. Karakteristik Covid-19 Varian Delta dan Varian Omicron pada Anak Characteristics of Delta and Omicron Variants of Covid-19 in Children. *Medical Scope Journal*. 2023;5(1):83–91.
79. Dos Santos PR, Dos Santos UR, de Santana Silva ÍTS, Fehlberg HF, Ferreira FB, Albuquerque GR, et al. Influence of SARS-CoV-2 variants on COVID-19 epidemiological and clinical profiles: a comparative analysis of two waves of cases. *Virol J*. 2024 Dec 1;21(1):260.
80. Fryer HR, Golubchik T, Hall M, Fraser C, Hinch R, Ferretti L, et al. Viral burden is associated with age, vaccination, and viral variant in a population-

representative study of SARS-CoV-2 that accounts for time-since-infection-related sampling bias. PLoS Pathog. 2023 Aug 1;19(8 August).

81. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Hopkins S, et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. 2021.
82. Rambaut A, Loman N, Pybus O, Barclay W, Barret J, Carabelli A, et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations [Internet]. 2020 [cited 2024 Nov 21]. Available from: <https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563>
83. Rodriguez SE, Bhattacharya M, Gravagnuolo AM, Shorthouse DR, Sunil S, Shastri J. SARS-CoV-2 variants: Impact on biological and clinical outcome. 2022;
84. Goethem N Van, Serrien B, Vandromme M, Thomas CW, Catteau L, Brondeel R, et al. Conceptual causal framework to assess the effect of SARS-CoV-2 variants on COVID-19 disease severity among hospitalized patients. Herman Van Oyen is editor of Archives of Public Health. 2021;79(185).
85. Ogawa F, Oi Y, Honzawa H, Misawa N, Takeda T, Kikuchi Y, et al. Severity predictors of COVID-19 in SARS-CoV-2 variant, Delta and Omicron period; single center study. PLoS One. 2022 Oct 1;17(10 October).
86. Esper FP, Adhikari TM, Tu ZJ, Cheng YW, El-Haddad K, Farkas DH, et al. Alpha to Omicron: Disease Severity and Clinical Outcomes of Major SARS-CoV-2 Variants. Journal of Infectious Diseases. 2023 Feb 1;227(3):344–52.
87. de Prost N, Audureau E, Préau S, Favory R, Guigon A, Bay P, et al. Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variants BA.2, BA.5 and BQ.1.1 in critically ill patients with COVID-19: a prospective, multicenter cohort study. Intensive Care Medicine Experimental . 2023 Dec 1;11(1).
88. Ward IL, Bermingham C, Ayoubkhani D, Gethings OJ, Pouwels KB, Yates T, et al. Risk of covid-19 related deaths for SARS-CoV-2 Omicron (B.1.1.529) compared with Delta (B.1.617.2): retrospective cohort study. The BMJ. 2022;
89. Aisyah DN, Mayadewi CA, Diva H, Kozlakidis Z, Siswanto, Adisasmito W. A spatial-temporal description of the SARSCoV-2 infections in Indonesia during the first six months of outbreak. PLoS One. 2020 Dec 1;15(12 December).

90. Zhu M, Zeng Q, Saputro BIL, Chew SP, Chew I, Frendy H, et al. Tracking the molecular evolution and transmission patterns of SARS-CoV-2 lineage B.1.466.2 in Indonesia based on genomic surveillance data. *Virol J*. 2022 Dec 1;19(1).
91. Rahmashani DA. Kasus Positif Covid-19 di Padang Meningkat Tajam, Dinkes : Masyarakat Banyak yang Abai Prokes... [Internet]. Kompas.com. 2021 [cited 2024 Jun 15]. Available from: <https://regional.kompas.com/read/2021/07/17/154104278/kasus-positif-covid-19-di-padang-meningkat-tajam-dinkes-masyarakat-banyak>
92. Rahmadhani GSP. Selama 2022, Positif Covid-19 di Padang Lebih dari 2.000 Kasus [Internet]. Kompas.com. 2022 [cited 2024 Jun 15]. Available from: <https://regional.kompas.com/read/2022/02/17/162736478/selama-2022-positif-covid-19-di-padang-lebih-dari-2000-kasus>
93. Rahmadhani KWA. Angka Positif Covid-19 Masih Tinggi di Kota Padang, Ini Penyebabnya [Internet]. Kompas.com. 2021 [cited 2024 Jun 15]. Available from: <https://regional.kompas.com/read/2021/08/05/222113778/angka-positif-covid-19-masih-tinggi-di-kota-padang-ini-penyebabnya>
94. Dipna Videlia Putsanra. Penyebab Meningkatnya Kasus Covid-19 Menurut Wamenkes [Internet]. Tirto.id. 2021 [cited 2024 Jun 15]. Available from: <https://tirto.id/penyebab-meningkatnya-kasus-covid-19-di-indonesia-menurut-wamenkes-ggjP>
95. Hasanah D. SUMBER POTENSIAL PENYEBARAN SARS-CoV-2 DARI LINGKUNGAN RUMAH SAKIT DAN PENTINGNYA PEMANTAUAN SANITASI RUMAH SAKIT UNTUK MENEKAN PANDEMI COVID-19 DI INDONESIA. *Majalah Kesehatan*. 2022;9(3).
96. Pemerintah Tingkatkan Kapasitas Deteksi Genom Virus SARS-CoV-2 [Internet]. Kementerian Kesehatan Republik Indonesia. 2021 [cited 2024 Nov 22]. Available from: <https://kemkes.go.id/id/pemerintah-tingkatkan-kapasitas-deteksi-genom-virus-sars-cov-2>
97. Indonesia dan WHO bekerja sama untuk lebih memahami tingkat infeksi SARS-CoV-2 dan kekebalan populasi sebagai bagian dari WHO Unity Study [Internet]. WHO. 2020 [cited 2024 Nov 22]. Available from: <https://www.who.int/indonesia/news/detail/02-07-2020-indonesia-dan-who-bekerja-sama-untuk-lebih-memahami-tingkat-infeksi-sars-cov-2-dan-kekebalan-populasi-sebagai-bagian-dari-who-unity-study>